Generic source disagrees . . .

Industry/Patient Alliance Says REMS Bills Raise Liability, Diversion Concerns

August 17, 2017 at 8:56 PM
Concerns over Risk Evaluation and Mitigation Strategies (REMS) abuse are largely misinformed and current reform proposals would create liability and diversion concerns for brand drug makers, an alliance of pharmaceutical companies and patient advocacy organizations argues in recent comments to FDA. But a generic drug source argues that the criticisms by the coalition, the AIMED Alliance, are false and should be dismissed if "we trust the FDA to do their job." FDA Commissioner Scott Gottlieb has spoken out against alleged...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.